LCN2 and acute kidney injury: Consequently, the usefulness of NGAL as a biomarker for diagnosing AKI has yet to be established, and further study is obviously required to obtain more data for mortality, dialysis requirement, ICU stay, length of hospital stay, and other relevant outcomes.